Pfizer is looking for cancer pipeline. Their bid for Astra continues to have huge problems.
I'm sure we don't need to remind Dr. Denner of their phone number. And don't forget the Pfizer rumor a few months ago; albeit from a ridiculously unreliable source.
The major attraction for PFE was the tax advantages of moving to England after the buyout. The feds are hip to this and making noises about neutralizing that tax move. While not comparable in size, Ariad does come with a substantial tax loss carry forward. Just sayin'.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.